Literature DB >> 20222796

Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.

David T MacLaughlin1, Patricia K Donahoe.   

Abstract

According to the 2008 American Cancer Society statistics, cancer remains the second leading cause of death in American today. Early detection, innovative surgery, new drugs and increased public education regarding avoidable risk factors, such as smoking, have had significant impact on the incidence and survival rates of many cancers, while overall death rates from all cancers have declined a modest 5% over the past 50 years. Ovarian cancer statistics, however, have not been as encouraging. Despite recent advances in the management of this disease, 5-year survival has not improved, and the search continues for rationally designed new treatments. Müllerian Inhibiting Substance is a strong candidate because it addresses many of the deficiencies of existing treatments. Namely, Müllerian Inhibiting Substance has little demonstrated toxicity, it complements the activity of known anticancer drugs, it is highly specific against cancers expressing its receptor and it inhibits the proliferation of drug-resistant tumors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20222796      PMCID: PMC3935316          DOI: 10.2217/fon.09.172

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


  121 in total

Review 1.  The Anti-Mullerian hormone and ovarian cancer.

Authors:  Antonio La Marca; Annibale Volpe
Journal:  Hum Reprod Update       Date:  2007-01-09       Impact factor: 15.610

2.  Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology.

Authors:  T Silberstein; D T MacLaughlin; I Shai; J R Trimarchi; G Lambert-Messerlian; D B Seifer; D L Keefe; A S Blazar
Journal:  Hum Reprod       Date:  2005-08-25       Impact factor: 6.918

3.  Mullerian inhibiting substance acts as a motor neuron survival factor in vitro.

Authors:  Pei-Yu Wang; Kyoko Koishi; Andrew B McGeachie; Michael Kimber; David T Maclaughlin; Patricia K Donahoe; Ian S McLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

4.  Mullerian Inhibiting Substance enhances subclinical doses of chemotherapeutic agents to inhibit human and mouse ovarian cancer.

Authors:  Rafael Pieretti-Vanmarcke; Patricia K Donahoe; Lisa A Pearsall; Daniela M Dinulescu; Denise C Connolly; Elkan F Halpern; Michael V Seiden; David T MacLaughlin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-06       Impact factor: 11.205

5.  Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness.

Authors:  Paul P Szotek; Rafael Pieretti-Vanmarcke; Peter T Masiakos; Daniela M Dinulescu; Denise Connolly; Rosemary Foster; David Dombkowski; Frederic Preffer; David T Maclaughlin; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

6.  Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.

Authors:  Jamie N Bakkum-Gamez; Giovanni Aletti; Kriste A Lewis; Gary L Keeney; Bijoy M Thomas; Isabelle Navarro-Teulon; William A Cliby
Journal:  Gynecol Oncol       Date:  2007-11-07       Impact factor: 5.482

7.  Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.

Authors:  Rafael Pieretti-Vanmarcke; Patricia K Donahoe; Paul Szotek; Thomas Manganaro; Mary K Lorenzen; James Lorenzen; Denise C Connolly; Elkan F Halpern; David T MacLaughlin
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

8.  Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology.

Authors:  Henry L Chang; Nima Pahlavan; Elkan F Halpern; David T MacLaughlin
Journal:  Gynecol Oncol       Date:  2009-04-08       Impact factor: 5.482

9.  The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor protein and mRNA in benign, borderline and malignant ovarian neoplasia.

Authors:  Jae Yen Song; Keun Young Chen; Sue Yeon Kim; Mee Ran Kim; Ki Sung Ryu; Jung Ho Cha; Chang Suk Kang; David T MacLaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2009-06       Impact factor: 5.650

10.  Anti-Mullerian-hormone-dependent regulation of the brain serine-protease inhibitor neuroserpin.

Authors:  Nathalie Lebeurrier; Séverine Launay; Richard Macrez; Eric Maubert; Hélène Legros; Arnaud Leclerc; Soazik P Jamin; Jean-Yves Picard; Stéphane Marret; Vincent Laudenbach; Philipp Berger; Peter Sonderegger; Carine Ali; Nathalie di Clemente; Denis Vivien
Journal:  J Cell Sci       Date:  2008-09-16       Impact factor: 5.285

View more
  23 in total

1.  Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk.

Authors:  Hazel B Nichols; Donna D Baird; Frank Z Stanczyk; Anne Z Steiner; Melissa A Troester; Kristina W Whitworth; Dale P Sandler
Journal:  Cancer Prev Res (Phila)       Date:  2015-04-14

2.  Prediagnostic circulating anti-Müllerian hormone concentrations are not associated with prostate cancer risk.

Authors:  Martha M Sklavos; Cindy Ke Zhou; Ligia A Pinto; Michael B Cook
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-08-26       Impact factor: 4.254

3.  Identification of characteristic molecular signature of Müllerian inhibiting substance in human HPV-related cervical cancer cells.

Authors:  Seong Jin Hwang; Min Jung Suh; Joo Hee Yoon; Mee Ran Kim; Ki Sung Ryu; Suk Woo Nam; Patricia K Donahoe; David T Maclaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2011-05-13       Impact factor: 5.650

4.  Expression of Müllerian inhibiting substance type II receptor and antiproliferative effects of MIS on human cervical cancer.

Authors:  Jae Yen Song; Hyun Hee Jo; Mee Ran Kim; Young Oak Lew; Ki Sung Ryu; Jung Ho Cha; Chang Suk Kang; Patricia K Donahoe; David T MacLaughlin; Jang Heub Kim
Journal:  Int J Oncol       Date:  2012-02-14       Impact factor: 5.650

5.  Reduced serum levels of anti-Müllerian hormone in females with inherited bone marrow failure syndromes.

Authors:  Martha M Sklavos; Pamela Stratton; Neelam Giri; Blanche P Alter; Sharon A Savage; Ligia A Pinto
Journal:  J Clin Endocrinol Metab       Date:  2014-11-18       Impact factor: 5.958

6.  Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Louise A Brinton; Brian L Egleston; Roni Falk; Renée T Fortner; Kathy J Helzlsouer; Annika Idahl; Rudolph Kaaks; Eva Lundin; Melissa Merritt; Charlotte Onland-Moret; Sabina Rinaldi; María-José Sánchez; Sabina Sieri; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley Tworoger; Kala Visvanathan; Vittorio Krogh; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Wei Zheng; Joanne F Dorgan
Journal:  Fertil Steril       Date:  2017-04       Impact factor: 7.329

7.  Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.

Authors:  Seungyoun Jung; Naomi Allen; Alan A Arslan; Laura Baglietto; Aurelio Barricarte; Louise A Brinton; Brian L Egleston; Roni T Falk; Renée T Fortner; Kathy J Helzlsouer; Yutang Gao; Annika Idahl; Rudolph Kaaks; Vittorio Krogh; Melissa A Merritt; Eva Lundin; N Charlotte Onland-Moret; Sabina Rinaldi; Helena Schock; Xiao-Ou Shu; Patrick M Sluss; Paul N Staats; Carlotta Sacerdote; Ruth C Travis; Anne Tjønneland; Antonia Trichopoulou; Shelley S Tworoger; Kala Visvanathan; Elisabete Weiderpass; Anne Zeleniuch-Jacquotte; Joanne F Dorgan
Journal:  Int J Cancer       Date:  2017-10-04       Impact factor: 7.396

8.  Plasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.

Authors:  A Heather Eliassen; Anne Zeleniuch-Jacquotte; Bernard Rosner; Susan E Hankinson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-03-09       Impact factor: 4.254

9.  Anti-Müllerian hormone deficiency in females with Fanconi anemia.

Authors:  Martha M Sklavos; Neelam Giri; Pamela Stratton; Blanche P Alter; Ligia A Pinto
Journal:  J Clin Endocrinol Metab       Date:  2014-01-17       Impact factor: 5.958

10.  The Müllerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained β-catenin signaling.

Authors:  Pradeep S Tanwar; Arno E Commandeur; LiHua Zhang; Makoto M Taketo; Jose M Teixeira
Journal:  Carcinogenesis       Date:  2012-09-07       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.